ArticleAnimals : an open access journal from MDPI2026
When Pain Outlasts Our Drugs: The Case for Sustained-Release Analgesia in Sheep.
Article in Animals : an open access journal from MDPI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Potential of Selective COX-2 Inhibitor Mavacoxib for Extended Analgesia in Sheep Husbandry.Animals : an open access journal from MDPI · 2026Article
- Toward functional integration of 3D-printed meniscal scaffolds: A materials-driven systematic review of preclinical evidence and translational framework.Journal of experimental orthopaedics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain associated with routine husbandry procedures in sheep can persist for several days or even weeks, yet current analgesic options, such as the non-steroidal anti-inflammatory drug (NSAID) meloxicam, typically provide only 24-36 h of analgesia. This mismatch between pain duration and analgesic coverage represents a fundamental limitation of current pain-management strategies in sheep. Sustained-release (SR) formulations are emerging as a promising approach to deliver longer-lasting pain relief from a single dose, reducing the need for repeated handling, and improving both animal welfare and farm efficiency. Emerging evidence highlights both the promise and limitations of different strategies to extend therapeutic coverage beyond 72 h. While preliminary results are encouraging, challenges remain in achieving consistent pharmacokinetic profiles and optimal peak concentrations. Advancing SR meloxicam formulations could support widespread uptake of welfare-focused innovations in the sheep industry. Although not yet widely available, sustained-release meloxicam represent a promising step towards making routine husbandry procedures more humane and efficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.